(Total Views: 512)
Posted On: 10/30/2022 7:25:09 PM
Post# of 154003
Thank you Sean.
We need more of this.
Leronlimab needs to be doing the talking, and it will again.
Maybe we will see data tomorrow. Data from the trial as derived from the External FDA Type GCP Auditors.
That data is the Top Line Data from the trial and should be Good News to the share price if that is in fact what they will be showing us.
We need more of this.
Leronlimab needs to be doing the talking, and it will again.
Maybe we will see data tomorrow. Data from the trial as derived from the External FDA Type GCP Auditors.
That data is the Top Line Data from the trial and should be Good News to the share price if that is in fact what they will be showing us.
(1)
(0)
